Navari R
Cancer Care Program Central and South America, World Health Organization, Indiana University School of Medicine South Bend, Indiana, USA.
Drugs Today (Barc). 2016 Aug;52(8):431-438. doi: 10.1358/dot.2016.52.8.2525738.
Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical issue which affects patients' quality of life as well as treatment decisions. Significant improvements in the control of CINV have occurred in the past 15 years with the introduction of new antiemetic agents: 5-HT3 receptor antagonists, tachykinin NK1 receptor antagonists and olanzapine. Aprepitant was the first NK1 receptor antagonist introduced (2003) for the prevention of CINV in combination with a 5-HT3 receptor antagonist and dexamethasone. Two additional NK1 receptor antagonists, netupitant and rolapitant, were approved by the FDA in 2014 and 2015, respectively. A description of rolapitant and its role in CINV will be presented, along with a comparison to the other NK1 receptor antagonists, aprepitant and netupitant.
化疗引起的恶心和呕吐（CINV）是一个重大的临床问题，它会影响患者的生活质量以及治疗决策。在过去15年中，随着新型止吐药物的引入，CINV的控制取得了显著进展：5-羟色胺3（5-HT3）受体拮抗剂、速激肽NK1受体拮抗剂和奥氮平。阿瑞匹坦是第一种被引入（2003年）用于与5-HT3受体拮抗剂和地塞米松联合预防CINV的NK1受体拮抗剂。另外两种NK1受体拮抗剂奈妥匹坦和罗拉匹坦分别于2014年和2015年获得美国食品药品监督管理局（FDA）批准。本文将介绍罗拉匹坦及其在CINV中的作用，并与其他NK1受体拮抗剂阿瑞匹坦和奈妥匹坦进行比较。
